Luc-André Granier, MD, PhD, founded Advicenne and has been Medical Director and Chairman of the Board since 2011. Luc-André Granier is an expert in the pharmaceutical development of innovative therapeutic products in the field of the central nervous system (CNS) with more than 25 years’ experience in the pharmaceutical (Eli Lilly and Co) and biotechnology (Synt:em, Forenap) industries. He has conducted a large number of clinical trials and led numerous programs for the development of drugs to treat neurological disorders, mainly in the fields of pain, migraine, neuro-degenerative diseases and psychiatric disorders. In particular, he successfully conducted the proof of concept study for the “blockbuster” duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in 2004. Dr Granier obtained his degree as a Doctor of Medicine and Doctor of Science (in Biochemistry and Molecular and Cellular Biology) at the Louis Pasteur University in Strasbourg, France. He is a member of several national and international scientific societies, in particular in the fields of pain (SFETD, IHS, IASP) and epilepsy (ILAE).
With more than 20 years of experience in the pharmaceutical industry, Dominique Costantini, MD has taken care of many therapeutic innovations in the international framework of oncology. During her career, she has occupied management positions within HMR (now Sanofi) where she led medico-marketing activities to commercialise products (notably in immunology, endocrinology, infectious illnesses, and oncology). Within this frame, she has participated in the development of various medicines, from their conception to their marketing authorisations.
In 1997, she founded and became the managing director of BioAlliance Pharma until 2011. BioAlliance Pharma notably originated Livatag®, an anti-cancer nanotechnology in primary liver cancer, now in Phase 3 (in Europe and the USA). Dominique Costantini led BioAlliance Pharma’s IPO on Euronext (2005). She is the source of many international industrial partnerships (Europe, USA, China, Japan and Korea). To date BioAlliance Pharma is the only French biotechnology company with two FDA registered products. Dominique Costantini is a doctor (Paris V university), who specialises in immunology. She co-founded OSE Pharma.
Co-founder and Member of the Supervisory Board of Auriga Partners, Bernard is an expert in Life Sciences and was behind successful investments such as BioAlliance Pharma (EuroNext : BIO), NicOx (EuroNext : COX). He is a member of the French Academy of Technologies.
Bernard began his career doing research into particle physics at the University of Orsay, the University of California at Berkeley, and CNRS, the French national scientific research center. He subsequently held senior posts at the French Ministry of Industry and Research, where he was in charge of promoting technology transfer from research institutions and of optimizing relations between Research and Industry. After 4 years in the Crédit Lyonnais setting up the bank’s Venture Capital arm, he joined Finovelec in 1990. Bernard is a graduate of the Ecole Polytechnique and has a PhD from the University of Orsay.
Celia Hart, PhD, MBA, is Investment Director at CEA Investissement . Celia has more than 20 years’ experience in the chemical and biotechnology sector. She did her PhD in protein engineering and metabolic engineering at Oxford University (UK) in a laboratory that worked closely with Industry (GSK, DSM). Celia then worked in the UK Biotechnology industry at Cambridge Antibody Technology (now Medimmune) where she was the Head of Lead Optimisation and led the R&D development of several therapeutic antibodies. Since then she has been assessing new business opportunities built on strong science at leading institutions (ESRF, CEA). She joined CEA Investissement (France) in 2005 and is now Investment Director and in charge of the life science sector. She serves (or has served) on the Board of several companies including Cytoo, Fermentalg (2014 IPO), ImmunId and Eviagenics, Bioaxial and Theranexus.Celia holds a degree in Chemistry from the University of Geneva (Switzerland), a PhD from the University of Oxford (UK) and an MBA from Grenoble Ecole de Management (France).
With a diploma from the Graduate School of Commerce, Cécile Thebault has been working for 28 years as a Capital Risk and Development Investor/LBO in SMEs. Since 1999, she has been responsible for the technological funds investment department managed by Sofimac Partners and for a Biosciences portfolio, with a position on different Boards of Directors of technological companies (Laboratoires Cyclopharma, Immun’ID, Biom’Up, Axess Vision, Opi, Metex, etc.) She assisted several Biotechnology companies from the initiation stage through to commercialisation or Stock Exchange listing (Genolife, OPI, Metex).
Senior Associate – Rhône Alpes Création, engineer graduated from EM Lyon and Arts et Métiers. Before joining Rhone Alpes Création, Gwenaël worked for Sigefi Venture Gestion (Siparex Group) as an associate. He is specialized in life sciences and cleantech seed companies investment.
He servers on the board of AMOEBA,I-TEN, SYNAPCEL, WINGIT